Hypothalamic serotonin transporters in subjects suspect for hypothalamic damage

Hypothalamic serotonin transporters in subjects suspect for hypothalamic damage - HypS-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36631

Enrollment

Registered

2010-09-20

Start date

2010-07-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypothalamic damage hypothalamic dysfunction

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: having pituitary insufficiency and suspicion of hypothalamic damage or having pituitary insufficiency and no suspicion of hypothalamic damage or (in case of controls) being healthy age between 18-75 years old

Exclusion criteria

Exclusion criteria: *Unwilling or unable to provide informed consent *Serious neuropsychiatric problems *Use of medication which interferes with serotonin metabolism (e.g. psychotropic medication like SSRIs or other antidepressants) and dopamin metabolism *Life-time ecstasy, amphetamine or cocaine use *Intravenous drug abuse *Participation in another study associated with exposure to ionizing radiation during the last 12 months *Pregnancy *Contra-indication for MRI

Design outcomes

Primary

Measure	Time frame
Difference in binding ratio in the hypothalamus of the radioligand [123I]FP-CIT to serotonin transporters between subjects with pituitary insufficiency and clinical suspect for hypothalamic damage, subjects with hypopituitarism without suspicion of hypothalamic damage and healthy age- and gender matched controls.	—

Secondary

Measure	Time frame
To define the optimal time-point of assessing central serotonin transporter binding with FP-CIT SPECT after injection of the radiotracer.	—

Countries

Netherlands

Outcome results